Small Bowel Capsule Endoscopy Findings in Patients Receiving Cellcept®

Inclusion Criteria: * Male or female patients between 18 and 75 years of age. * Recipients of first or second cadaveric, living unrelated or living related kidney transplant. * Recipients who are at least 4 weeks post renal transplantation with stable renal function. * Patients who have used MMF at least 10 days and are currently receiving MMF. (up to 3g/day dosage allowed) * Patients with at least one moderate or severe upper or lower GI complaints. * Patients' immunosuppressive regimen other than steroids as well as medication for treatment of GI symptoms must be unchanged for at least 1 week prior to study start. * Females of childbearing potential must have a negative pregnancy test prior to the inclusion period. Effective contraception must be used during the trial, and for 4 weeks following discontinuation of the study medication. * Patients who are willing and able to participate in the full course of the study and from whom written informed consent has been obtained. Exclusion Criteria: * Multi-organ transplant patients or previous transplant with any other organ different from kidney. * The presence of a severe GI disorder. History of a significant GI disorder prior to transplant that has remained unchanged since transplant and/or the introduction of MMF will exclude patient. * Evidence of any GI disorder induced by an infection, underlying medical condition, or concomitant medication other than MMF. * Modification of GI medication or MMF dose within last 1 week. * Evidence of graft rejection, treatment of acute rejection, or unstable renal function within 4 weeks prior to the Baseline visit. * Patients who have received an investigational immunosuppressive drug within 4 weeks prior to study entry. * Patients with a history of malignancy within the last five years, except excised squamous or basal cell carcinoma of the skin. * Pregnant or nursing women. * Patients with thrombocytopenia (\<75,000/mm3), with an absolute neutrophil count of \<1,500/mm3 and/or leukocytopenia (\<3,500/mm3), and/or hemoglobin \<9.0 g/dL prior to enrollment. * Presence of clinically significant pyrexia and/or infection requiring continued therapy. * Evidence of severe liver disease \[incl. abnormal liver profile i.e. AST, ALT or total bilirubin = 3 times the upper limit of normal\]. * Patients who have any anatomical GI tract defects which have risk of capsule getting stuck such as tumor or previous abdominal surgery. * Abnormal physical or laboratory findings of clinical significance within 2 weeks of inclusion which would interfere with the objectives of the study. * Patients with symptoms of significant illness or evidence of current drug and/or alcohol abuse. * Inability to self-administer the GSRS \& OTE questionnaire. * Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer. * History of hypersensitivity to any of the study drugs or to drugs with similar chemical structures.